A Treatment for Refractory High Ileostomy Output

Area of Science:

• Gastroenterology
• Endocrinology
• Pharmacology

Background:

• Short bowel syndrome (SBS) significantly impairs quality of life and increases healthcare expenditures.
• Parenteral nutrition (PN) is a common management strategy, but complications and costs remain significant.
• Optimizing intestinal adaptation and reducing fluid/nutrient losses are key therapeutic goals in SBS.

Observation:

• A case study involving a patient with short bowel syndrome experiencing high ostomy output.
• The patient was not entirely dependent on parenteral nutrition, suggesting a potential for oral or subcutaneous therapies.
• Teduglutide, a glucagon-like peptide 2 (GLP-2) analog, was administered to manage the high ostomy output.

Findings:

• Successful reduction in high ostomy output was achieved with teduglutide therapy.
• Teduglutide demonstrated efficacy in improving fluid and nutrient balance in this SBS patient.
• The treatment was well-tolerated, contributing to a better clinical status.

Implications:

• Teduglutide represents a viable therapeutic option for managing high ostomy output in short bowel syndrome.
• This approach may enhance palliative care strategies for SBS patients, potentially reducing reliance on intensive interventions.
• Further research into teduglutide's cost-effectiveness and long-term benefits in diverse SBS populations is warranted.